Abstract 185P
Background
LIF is an interleukin 6 class cytokine that plays a crucial role in the development of many solid tumors. Herein, we identify the elusive role of LIF in clear cell renal cell carcinoma (ccRCC) and its impact on tumor immune microenvironment.
Methods
The human cancer genome atlas (TCGA) was utilized to obtain ccRCC clinicopathological and expression data. The prognostic utility of LIF expression in ccRCC was evaluated using univariate and multivariate Cox logistic regression analysis. Co-expressed genes were explored using LinkedOmics and their biological roles were identified using gene set enrichment analysis (GSEA) through KEGG pathways terminology. The immune microenvironment was evaluated using Tumor IMmune Estimation Resource (TIMER 2.0). Correlations between LIF expression and immune-related genes were obtained using the Gene Expression Profiling Interactive Analysis (GEPIA).
Results
High LIF expression is associated with shortened overall survival (HR: 1.828, 95% CI: 1.358-2.460, P < .0001) in TCGA ccRCC cohort. Multivariate Cox logistic regression analysis identified LIF expression as an independent prognostic variable (HR: 0.48, 95% CI: 0.303-0.759, P = .002). GSEA showed enrichment in IL-17, TNF, JAK-STAT and NF-kB signaling pathways besides cytokine-cytokine receptor interaction, transcriptional misregulation in cancer, complement and coagulation cascades. LIF expression is positively corelated with immunosuppressive cellular elements including Tregs (ρ = 0.14, Q = 0.012), M2 macrophages (ρ = 0.25, Q < .0001), and myeloidderived suppressor cells (ρ = 0.18, Q value < .001). In addition, LIF corelated significantly with Tregs-related genes including FOXP3 (ρ = 0.28, P < .0001), CCR8 (ρ = 0.23, P < .0001), and TGF-β (ρ = 0.38, P < .0001). M2 macrophages-related genes were also significantly corelated with LIF expression as in CD163 (ρ = 0.30, P < .0001), VSIG4 (ρ = 0.27, P < .0001), and MS4A4A (ρ = 0.24, P < .0001). Immune check points genes were also influenced by LIF expression including CTLA4 (ρ = 0.25, P < .0001) and LAG3 (ρ = 0.21, P < .0001).
Conclusions
LIF upregulation corelates with poor prognosis in ccRCC and induces an immune suppressed microenvironment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display